Immuneering

28 articles with Immuneering

• Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights 

  5/10/2022

  Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

• Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day

  5/5/2022

  Immuneering Corporation today announced that management will participate in Citi’s Biopharma VIRTUAL Co-Panel Day to discuss software, artificial intelligence and bioinformatics in drug development.

• Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

  4/1/2022

  Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will participate in Piper Sandler’s AI/ML Investor Conference to discuss software, artificial intelligence and bioinformatics in drug development.

• Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

  3/24/2022

  Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will present at the 21st Annual Needham Virtual Healthcare Conference to share commentary around the Company’s pipeline, platform, and business strategy.

• Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/10/2022

  Immuneering Corporation reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business updates.

• Immuneering Announces Participation in March Investor Conferences

  2/24/2022

  Immuneering Corporation today announced that management will participate in two March investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.

• Immuneering Announces Participation in Upcoming Investor Conferences - Jan 24, 2022

  1/24/2022

  Immuneering Corporation announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in upcoming investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

• 

  BioSpace Movers & Shakers, Jan. 21

  1/21/2022

  Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. 

• Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise

  1/18/2022

  Immuneering Corporation today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors.

• 

  Movers & Shakers, Jan. 7

  1/7/2022

  With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.

• Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

  1/3/2022

  Immuneering Corporation today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately.

• Immuneering Added to the Nasdaq Biotechnology Index

  12/16/2021

  Immuneering Corporation today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 20, 2021.

• Immuneering Announces Participation in December 2021 Investor Conferences

  11/18/2021

  Immuneering Corporation announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in several December investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

• Immuneering to Participate in Jefferies 2021 London Healthcare Conference

  11/10/2021

  Immuneering Corporation today announced that Company management will participate in the upcoming Jefferies 2021 London Healthcare Conference, taking place virtually and in-person from November 16-19, 2021 in London, England.

• Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

  11/9/2021

  Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

• Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/11/2021

  Immuneering Corporation today announced that three key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that took place virtually from October 7-10, 2021.

• Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/1/2021

  Immuneering Corporation announced that several key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place virtually from October 7-10, 2021.

• Immuneering Announces Inclusion in the Russell 2000® Index

  9/20/2021

  Immuneering Corporation today announced that Immuneering Corporation has been selected to be added to the Russell 2000® Index effective September 20, 2021, after the close of the U.S. equity markets.

• Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

  9/9/2021

  Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Immuneering to Participate in September 2021 Investor Conferences

  9/2/2021

  Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, announced that Company management will participate in two upcoming virtual investor conferences in September 2021.